Subscribe to RSS
DOI: 10.1590/0004-282X-ANP-2021-0001
Mortality associated with cysticercosis in a historical cohort from Britain
Mortalidade associada à cisticercose em uma coorte histórica da Grã-BretanhaABSTRACT
Background: The burden of premature mortality associated with human cysticercosis is largely ignored mainly due to poor record-keeping in Taenia solium endemic regions. Objective: To document mortality and survival characteristics of an historical cohort with cysticercosis. Methods: The years of onset of symptoms and death untill 1957 were extracted from published reports of a British military cohort (n=450) examined in London in the early twentieth century. Data were entered into a Kaplan Meier survival analysis with the presence (or absence) of clinical manifestations as independent variables, which were then fitted into a Cox proportional hazards model to determine their significance. Results: Cysticercosis was responsible for 24 (52.2%) of 46 deaths in the first 15 years of follow-up in comparison to 7 (19.4%) of 36 deaths in the 20-40 years of follow-up period. In the univariate and Cox analyses, intracranial hypertension (hazard ratio [HR]: 8.26; CI: 4.71, 14.49), ocular cysticercosis (HR: 6.60; CI: 3.04, 14.33), and mental disorder (HR: 3.98; CI: 2.22, 7.13) but not epilepsy (HR: 0.66; CI: 0.20, 2.18) were associated with mortality. Over half of all deaths in the first 15 years of follow-up were attributed to cysticercosis. Conclusions: Several deaths occurred early after acquiring cysticercotic infection. Intracranial hypertension, ocular cysticercosis, and mental disorder but not epilepsy were predictors of mortality in this cohort.
RESUMO
Antecedentes: O fardo da mortalidade prematura associada à cisticercose humana é amplamente ignorado, principalmente devido à má manutenção de registros nas regiões endêmicas de Taenia solium. Objetivo: Documentar as características de mortalidade e sobrevivência de uma coorte histórica com cisticercose. Métodos: Os anos de início dos sintomas e morte até 1957 foram extraídos de relatórios publicados de uma coorte militar britânica (n = 450) examinada em Londres no início do século XX. Os dados foram inseridos em uma análise de sobrevida de Kaplan Meier com a presença (ou ausência) de manifestações clínicas como variáveis independentes, que foram então ajustadas em um modelo de risco proporcional de Cox para determinar sua significância. Resultados: A cisticercose foi responsável por 24 (52,2%) de 46 óbitos nos primeiros 15 anos de seguimento em comparação com 7 (19,4%) de 36 óbitos nos 20-40 anos de seguimento. Nas análises univariadas e de Cox, hipertensão intracraniana (razão de risco [HR]: 8,26; IC: 4,71, 14,49), cisticercose ocular (HR: 6,60; IC: 3,04, 14,33) e transtorno mental (HR: 3,98; IC: 2,22 , 7,13), mas não epilepsia (HR: 0,66; IC: 0,20, 2,18) foram associados com mortalidade. Mais da metade de todas as mortes nos primeiros 15 anos de acompanhamento foram atribuídas à cisticercose. Conclusões: Várias mortes ocorreram logo após a aquisição da infecção cisticercótica. Hipertensão intracraniana, cisticercose ocular e transtorno mental, mas não epilepsia, foram preditores de mortalidade nesta coorte.
Authors’ contributions:
GS and JWS: conceived the study; GS undertook the statistical analysis and drafted the paper; GS, PC and JWS critically reviewed, revised the manuscript and provided substantial intellectual input.
Publication History
Received: 27 February 2021
Accepted: 13 May 2021
Article published online:
30 January 2023
© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Garcia HH, Del Brutto OH. Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4 (10) 653-661
- 2 Carpio A, Fleury A, Romo ML, Abraham R. Neurocysticercosis: the good, the bad, and the missing. Expert Rev Neurother 2018; 18 (04) 289-301 https://doi.org/10.1080/14737175.2018.1451328
- 3 Sorvillo FJ, De Giorgio C, Waterman SH. Deaths from cysticercosis in the United States. Emerg Infect Dis 2007; 13 (02) 230-235 https://doi.org/10.3201/eid1302.060527
- 4 Sorvillo FJ, Portigal L, De Giorgio C, Smith L, Waterman SH, Berlin GW. et al. Cysticercosis-related deaths, California. Emerg Infect Dis 2004; 10 (03) 465-469 https://doi.org/10.3201/eid1003.020749
- 5 De Giorgio CM, Hoston I, Oviedo S, Sorvillo F. Deaths associated with cysticercosis. Report of three cases and review of the literature. Neurosurg Focus 2002; 12 (06) e2 https://doi.org/10.3171/foc.2002.12.6.3
- 6 Santo AH. Cysticercosis-related mortality in the state of São Paulo, Brazil, 1985-2004: a study using multiple causes of death. Cad Saúde Pública 2007; 23 (12) 2917-2927 https://doi.org/10.1590/S0102-311X2007001200013
- 7 MacArthur WP. Cysticercosis as a cause of epilepsy in man. Trans Roy Soc Trop Med Hyg 1933; 27: 525-528
- 8 MacArthur WP. Cysticercosis as seen in the British Army, with special reference to the production of epilepsy. J Roy Army Med Corps 1934; 62: 241-259
- 9 Dixon HBF, Smithers DW. Epilepsy in cysticercosis (Taenia solium): a study of seventy-one cases. Q J Med 1934; 3 (04) 603-616 https://doi.org/10.1093/qjmed/3.4.603
- 10 Dixon HBF, Smithers DW. Cysticercosis (Taenia solium). J Royal Army Med Corps 1935; 64: 227-234
- 11 Dixon HBF, Hargreaves WH. Cysticercosis (Taenia solium) a further ten years' clinical study, covering 284 cases. Q J Med 1944; 13 (04) 107-122 https://doi.org/10.1093/oxfordjournals.qjmed.a066444
- 12 Dixon HBF, Lipscomb FM. Cysticercosis: an analysis and follow-up of 450 cases Medical Research Council, Special report series, No. 299. London (UK): H.M. Stationery Office; 1961
- 13 Singh G, Sander JW. Historical perspective: the British contribution to the understanding of neurocysticercosis. J Hist Neurosci 2019; 28 (03) 332-344 https://doi.org/10.1080/0964704X.2018.1564523
- 14 Del Brutto OH, García HH. Taenia solium cysticercosis -- The lessons of history. J Neurol Sci 2015; 359 1-2 392-395 https://doi.org/10.1016/j.jns.2015.08.011
- 15 O'Keefe KA. Cysticercosis in the United States: A nationwide hospitalization study assessing burden of disease, fatality risk factors and economic impact of infection. dissertation Los Angeles, CA Los Angeles, CA: University of California; 2013 76.
- 16 Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg 1987; 66 (05) 686-689 https://doi.org/10.3171/jns.1987.66.5.0686
- 17 Del Brutto OH, Sotelo J, Aguirre R, Díaz-Calderón E, Alarcón TA. Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol 1992; 49 (05) 535-538 https://doi.org/10.1001/archneur.1992.00530290123021
- 18 Wadia N, Desai S, Bhatt M. Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel. Brain 1988; 111 (03) 597-614 https://doi.org/10.1093/brain/111.3.597
- 19 Rangel R, Torres B, Del Brutto O, Sotelo J. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg 1987; 36 (02) 387-392 https://doi.org/10.4269/ajtmh.1987.36.387
- 20 Stepien L. Cerebral cysticercosis in Poland. Clinical symptoms and operative results in 132 cases. J Neurosurg 1962; 19: 505-513 https://doi.org/10.3171/jns.1962.19.6.0505
- 21 Colli BO, Martelli N, Assirati Júnior JA, Machado HR, Salvarani CP, Sassoli VP. et al. Cysticercosis of the central nervous system. I. surgical treatment of cerebral cysticercosis: a 23 years experience in the hospital das clinicas of Ribeirão Preto Medical School. Arq Neuropsiquiatr 1994; 52 (02) 166-186 https://doi.org/10.1590/s0004-282x1994000200006
- 22 Proaño JV, Madrazo I, Avelar F, López Félix B, Díaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001; 345 (12) 879-885 https://doi.org/10.1056/NEJMoa010212
- 23 Pupo PP, Cardoso W, Reis JB. et al. Sobre a cisticercose encefálica. Estudo clínico, anatomopatológico, radiológico e do liquido cefalo-raqueano. Archivos da Assistência aos Psicopatas de São Paulo 1946; 10-11 (3-123)
- 24 Forlenza OV, Vieira Filho AH, Nobrega JP, Machado LR, Barros NG, Camargo CH. et al. Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry 1997; 62 (06) 612-616 https://doi.org/10.1136/jnnp.62.6.612
- 25 Levira F, Thurman DJ, Sander JW, Hauser WA, Hesdorffer DC, Masanja H. et al. Premature mortality of epilepsy in low- and middle-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia 2017; 58 (01) 6-16 https://doi.org/10.1111/epi.13603
- 26 Fan X, Li Y, Shan X, You G, Wu Z, Li Z. et al. Seizures at presentation are correlated with better survival outcomes in adult diffuse glioma: a systematic review and meta-analysis. Seizure 2018; 59: P16-P23 https://doi.org/10.1016/j.seizure.2018.04.018
- 27 Singh G, Rajshekhar V, Murthy JM, Prabhakar S, Modi M, Khandelwal N. et al. A diagnostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology 2010; 75 (24) 2236-2245 https://doi.org/10.1212/WNL.0b013e31820202dc
- 28 Del Brutto OH. Single parenchymal brain cysticercus in the acute encephalitic phase: definition of a distinct form of neurocysticercosis with a benign prognosis. J Neurol Neurosurg Psychiatry 1995; 58 (02) 247-249 https://doi.org/10.1136/jnnp.58.2.247
- 29 Robles C, Chavarria MC. Presentactión de un caso clínio de cisticercosis cerebral tratado mèdicamente con un nuevo fàrmaco: praziquantel. Salud Publica Mex 1979; 21 (05) 603-618
- 30 Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for neurocysticercosis. Arch Intern Med 1987; 147 (04) 738-741 https://doi.org/10.1001/archinte.1987.00370040120021
- 31 Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia 2012; 53 (Suppl. 08) 26-39 https://doi.org/10.1111/epi.12026
- 32 Merritt HH, Putnam TJ. Landmark article Sept 17, 1938: Sodium diphenyl hydantoinate in the treatment of convulsive disorders. By H. Houston Merritt and Tracy J. Putnam.. JAMA 1984; 251 (08) 1062-1067 https://doi.org/10.1001/jama.251.8.1062
- 33 Neligan A, Shorvon SD. The history of status epilepticus and its treatment. Epilepsia 2009; 50 50(3 Suppl 3) 56-68 https://doi.org/10.1111/j.1528-1167.2009.02040.x